By Professor Paul De Souza

Journal articles

Panizza BJ; de Souza P; Cooper A; Roohullah A; Karapetis CS; Lickliter JD, 2019, 'Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46)', EBioMedicine, 50, pp. 433 - 441, http://dx.doi.org/10.1016/j.ebiom.2019.11.037

Weller M; Reardon D; Brandes A; Sampson J; Mulholland P; Wick A; Baehring J; Ahluwalia M; Roth P; Bähr O; Phuphanich S; Sepulveda J; de Souza P; Sahebjam S; Potter V; Tatsuoka K; Taitt C; Zwirtes R; Omuro A; Lim M, 2019, 'ATIM-47. NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: EXPLORATORY ANALYSIS OF MGMT METHYLATION STATUS AND BASELINE CORTICOSTEROID USE', Neuro-Oncology, 21, pp. vi12 - vi12, http://dx.doi.org/10.1093/neuonc/noz175.045

Ding PN; Becker T; Bray V; Chua W; Ma Y; Xu B; Lynch D; de Souza P; Roberts T, 2019, 'Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent-line osimertinib', Thoracic Cancer, 10, pp. 1879 - 1884, http://dx.doi.org/10.1111/1759-7714.13154

Lim SHS; Ip E; Ng W; Chua W; Asghari R; Roohullah A; Descallar J; Henderson C; Spring K; de Souza P; King MT, 2019, 'Health-related quality of life during chemoradiation in locally advanced rectal cancer: Impacts and ethnic disparities', Cancers, 11, http://dx.doi.org/10.3390/cancers11091263

Ding PN; Becker TM; Bray VJ; Chua W; Ma YF; Lynch D; Po J; Luk AWS; Caixeiro N; de Souza P; Roberts TL, 2019, 'The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study', Lung Cancer, 134, pp. 187 - 193, http://dx.doi.org/10.1016/j.lungcan.2019.06.021

Nimir M; Ma Y; Jeffreys SA; Opperman T; Young F; Khan T; Ding P; Chua W; Balakrishnar B; Cooper A; Souza PD; Becker TM, 2019, 'Detection of AR-v7 in liquid biopsies of castrate resistant prostate cancer patients: A comparison of AR-v7 analysis in circulating tumor cells, circulating tumor RNA and exosomes', Cells, 8, http://dx.doi.org/10.3390/cells8070688

Aghajani MJ; Roberts TL; Yang T; McCafferty CE; Caixeiro NJ; DeSouza P; Niles N, 2019, 'Elevated levels of soluble pd-l1 are associated with reduced recurrence in papillary thyroid cancer', Endocrine Connections, 8, pp. 1040 - 1051, http://dx.doi.org/10.1530/EC-19-0210

Basch EM; Scholz M; de Bono JS; Vogelzang N; de Souza P; Marx G; Vaishampayan U; George S; Schwarz JK; Antonarakis ES; O'Sullivan JM; Kalebasty AR; Chi KN; Dreicer R; Hutson TE; Dueck AC; Bennett AV; Dayan E; Mangeshkar M; Holland J; Weitzman AL; Scher HI, 2019, 'Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint', European Urology, 75, pp. 929 - 937, http://dx.doi.org/10.1016/j.eururo.2018.11.033

Clingan PR; Ackland SP; Brungs D; de Souza P; Aghmesheh M; Garg MB; Ranson RD; Parker S; Jokela R; Ranson M, 2019, 'First-in-human phase I study of infusional and bolus schedules of Deflexifol, a novel 5-fluorouracil and leucovorin formulation, after failure of standard treatment', Asia-Pacific Journal of Clinical Oncology, 15, pp. 151 - 157, http://dx.doi.org/10.1111/ajco.13144

Naher S; Padinharakam S; Balakrishnar B; Chua W; Descallar J; Adams D; de Souza P; Harrison M; Lim S, 2019, 'Patterns of Presentation and Treatment Outcomes of Non–clear-cell Renal Cell Carcinoma and Sarcomatoid Renal Cell Carcinoma Patients in 2 Tertiary Referral Centers in Sydney, Australia', Clinical Genitourinary Cancer, 17, pp. e565 - e569, http://dx.doi.org/10.1016/j.clgc.2019.02.006

Cao J; Zhang P; De Souza PL; Gao B; Voskoboynik M; Ji D; Shen W; Yang S; Zhou Y; Zhang R; Lickliter JD; Hoon S-N; Palmieri D; Cai S; Tian YE; Ma N; Xu C; Yang S; Zhang S; Xu B, 2019, 'Pooled analysis of phase I dose-escalation and dose cohort expansion studies of IMP4297, a novel PARP inhibitor, in Chinese and Australian patients with advanced solid tumors.', JOURNAL OF CLINICAL ONCOLOGY, 37, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.3059

Broom A; Kirby E; Kokonavic R; Woodland L; Wyld D; de Souza P; Koh S; Lwin Z, 2019, 'Individualising difference, negotiating culture: Intersections of biography and cancer care', Health, http://dx.doi.org/10.1177/1363459319829192

Po JW; Ma Y; Balakrishna B; Brungs D; Azimi F; De Souza P; Becker TM, 2019, 'Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status', PLoS ONE, 14, http://dx.doi.org/10.1371/journal.pone.0211866

Singh P; de Souza P; Scott KF; Hall BM; Verma ND; Becker TM; Toh JWT; Sajinovic M; Spring KJ, 2019, 'Biomarkers in immune checkpoint inhibition therapy for cancer patients: what is the role of lymphocyte subsets and PD1/PD-L1?', Translational Medicine Communications, 4, http://dx.doi.org/10.1186/s41231-019-0032-9

Powderly J; Spira A; Gutierrez R; DiRenzo D; Udyavar A; Karakunnel JJ; Rieger A; Colabella J; Lai DW; de Souza P, 2019, 'Phase I evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies', Annals of Oncology, 30, pp. v493 - v493, http://dx.doi.org/10.1093/annonc/mdz253.032

Roohullah A; Cooper A; Lomax AJ; Aung J; Barge A; Chow L; McHale M; Desai J; Whittle JR; Tran B; de Souza P; Horvath LG, 2018, 'A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers', Investigational New Drugs, 36, pp. 886 - 894, http://dx.doi.org/10.1007/s10637-018-0588-7

Ho V; Chung L; Singh A; Lea V; Abubakar A; Lim SH; Ng W; Lee M; de Souza P; Shin JS; Lee CS, 2018, 'Overexpression of the MRE11-RAD50-NBS1 (MRN) complex in rectal cancer correlates with poor response to neoadjuvant radiotherapy and prognosis', BMC Cancer, 18, http://dx.doi.org/10.1186/s12885-018-4776-9

Brungs D; Aghmesheh M; de Souza P; Carolan M; Clingan P; Rose J; Ranson M, 2018, 'Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer', Clinical Colorectal Cancer, 17, pp. e549 - e555, http://dx.doi.org/10.1016/j.clcc.2018.05.004

Ding PN; Ma YF; Roberts TJ; Chua W; Bray VJ; Lynch D; Burke D; Souza PD; Becker TM, 2018, 'Droplet Digital PCR Based Detection of EGFR Mutations in Advanced Lung Cancer Patient Liquid Biopsies: A Comparison of Circulating Tumour DNA Extraction Kits', Journal of Molecular Biomarkers & Diagnosis, 09, http://dx.doi.org/10.4172/2155-9929.1000397

Po JW; Roohullah A; Lynch D; DeFazio A; Harrison M; Harnett PR; Kennedy C; de Souza P; Becker TM, 2018, 'Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin', Journal of Circulating Biomarkers, 7, http://dx.doi.org/10.1177/1849454418782617

de Souza PL; Messina M; Minns I; Shavdia M; Chikhladze N; Kelly G, 2018, 'A phase 1 study of NOX66 in combination with carboplatin in patients with end stage solid tumours.', Journal of Clinical Oncology, 36, pp. 2585 - 2585, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.2585

Campbell DH; Lund ME; Nocon AL; Cozzi PJ; Frydenberg M; De Souza P; Schiller B; Beebe-Dimmer JL; Ruterbusch JJ; Walsh BJ, 2018, 'Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer', PLoS ONE, 13, http://dx.doi.org/10.1371/journal.pone.0196017

Aghajani M; Graham S; McCafferty C; Shaheed CA; Roberts T; Desouza P; Yang T; Niles N, 2018, 'Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 Expression in Patients with Non-Medullary Thyroid Cancer: A Systematic Review and Meta-Analysis', Thyroid, 28, pp. 349 - 361, http://dx.doi.org/10.1089/thy.2017.0441

Harris BHL; Walsh JL; Neciunaite R; Manders P; Cooper A; De Souza P, 2018, 'Ring a ring o'roses, a patient with Kaposi's? Pazopanib, pazopanib, it might go away. Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy', Clinical and Experimental Dermatology, 43, pp. 234 - 236, http://dx.doi.org/10.1111/ced.13302

Brungs D; Lynch D; Luk AWS; Minaei E; Ranson M; Aghmesheh M; Vine KL; Carolan M; Jaber M; De Souza P; Becker TM, 2018, 'Cryopreservation for delayed circulating tumor cell isolation is a valid strategy for prognostic association of circulating tumor cells in gastroesophageal cancer', World Journal of Gastroenterology, 24, pp. 810 - 818, http://dx.doi.org/10.3748/wjg.v24.i7.810

de Souza PL; Wong S; Sewak S; Kotasek D; Keam B; Chung J; Erbeck N; Han J; Dezzani L; Ahmad Q; Mainwaring PN, 2018, 'Phase II study of sequential first-line pazopanib (PAZ) followed by everolimus (EVE) in patients (pts) with advanced or metastatic renal cell carcinoma (RCC) (CATChEz Study).', JOURNAL OF CLINICAL ONCOLOGY, 36, http://dx.doi.org/10.1200/JCO.2018.36.6_suppl.648

Razdan A; de Souza P; Roberts TL, 2018, 'Role of microRNAs in treatment response in prostate cancer', Current Cancer Drug Targets, 18, pp. 929 - 944, http://dx.doi.org/10.2174/1568009618666180315160125

Bi L; Xie C; Yao M; Thae Hnit SS; Vignarajan S; Wang Y; Wang Q; Xi Z; Xu H; Li Z; de Souza P; Tee A; Wong M; Liu T; Zhao X; Zhou J; Xu L; Dong Q, 2018, 'The histone chaperone complex FACT promotes proliferative switch of G0 cancer cells', International Journal of Cancer, 145, pp. 164 - 178, http://dx.doi.org/10.1002/ijc.32065

Ho V; Chung L; Singh A; Lea V; Revoltar M; Lim SH; Tut TG; Ng W; Lee M; de Souza P; Shin JS; Lee CS, 2017, 'Early postoperative low expression of RAD50 in rectal cancer patients associates with disease-free survival', Cancers, 9, pp. 163, http://dx.doi.org/10.3390/cancers9120163

Callari M; Wong S; Lu H; Aldrich-Wright J; De Souza P; Stenzel MH, 2017, 'Drug induced self-assembly of triblock copolymers into polymersomes for the synergistic dual-drug delivery of platinum drugs and paclitaxel', Polymer Chemistry, 8, pp. 6289 - 6299, http://dx.doi.org/10.1039/c7py01162h

Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH; Campian J; Becker K; Barnett G; Nicholas G; Desjardins A; Benkers T; Wagle N; Groves M; Kesari S; Horvath Z; Merrell R; Curry R; O'Rourke J; Schuster D; Mrugala M; Jensen R; Trusheim J; Lesser G; Belanger K; Sloan A; Purow B; Fink K; Raizer J; Schulder M; Nair S; Peak S; Brandes A; Mohile N; Landolfi J; Olson J; Jennens R; DeSouza P; Robinson B; Crittenden M; Shih K; Flowers A; Ong S; Connelly J; Hadjipanayis C; Giglio P; Mott F; Mathieu D; Lessard N; Sepulveda SJ; Lövey J; Wheeler H; Inglis PL; Hardie C; Bota D; Lesniak M; Portnow J; Frankel B; Junck L; Thompson R; Berk L; McGhie J; Macdonald D; Saran F; Soffietti R; Blumenthal D; André de SBCM; Nowak A; Singhal N; Hottinger A; Schmid A; Srkalovic G; Baskin D; Fadul C; Nabors L; LaRocca R; Villano J; Paleologos N; Kavan P; Pitz M; Thiessen B, 2017, 'Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial', The Lancet Oncology, 18, pp. 1373 - 1385, http://dx.doi.org/10.1016/S1470-2045(17)30517-X

Callari M; De Souza PL; Rawal A; Stenzel MH, 2017, 'The Effect of Drug Loading on Micelle Properties: Solid-State NMR as a Tool to Gain Structural Insight', Angewandte Chemie - International Edition, 56, pp. 8441 - 8445, http://dx.doi.org/10.1002/anie.201701471

Callari M; De Souza PL; Rawal A; Stenzel MH, 2017, 'The Effect of Drug Loading on Micelle Properties: Solid‐State NMR as a Tool to Gain Structural Insight', Angewandte Chemie, 129, pp. 8561 - 8565, http://dx.doi.org/10.1002/ange.201701471

Ackland SP; Garg MB; Ranson M; Jokela R; Brungs D; Aghmesheh M; Tafreshi A; Ranson RD; Parker S; De Souza PL; Clingan PR, 2017, 'Deflexifol (a novel formulation of 5FU): Pharmacokinetics in a phase 1 trial in comparison to 5FU.', Journal of Clinical Oncology, 35, pp. 2530 - 2530, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.2530

Clingan PR; Ackland SP; Ranson M; Brungs D; Aghmesheh M; Tafreshi A; Garg MB; Parker S; Henderson A; Jokela R; De Souza PL, 2017, 'Deflexifol (a novel formulation of 5FU): Phase 1 dose escalation study of infusional and bolus schedules after failure of standard treatment.', Journal of Clinical Oncology, 35, pp. 2529 - 2529, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.2529

Luk AWS; Ma Y; Ding PN; Young FP; Chua W; Balakrishnar B; Dransfield DT; De Souza P; Becker TM, 2017, 'CTC-mRNA (AR-V7) analysis from blood samples—impact of blood collection tube and storage time', International Journal of Molecular Sciences, 18, http://dx.doi.org/10.3390/ijms18051047

Brungs D; Aghmesheh M; de Souza P; Ng W; Chua W; Carolan M; Clingan P; Healey E; Rose J; Tubaro T; Ranson M, 2017, 'Sidedness is prognostic in locoregional colon cancer: An analysis of 9509 Australian patients', BMC Cancer, 17, pp. 251, http://dx.doi.org/10.1186/s12885-017-3255-z

Del Re M; Fogli S; Derosa L; Massari F; De Souza P; Crucitta S; Bracarda S; Santini D; Danesi R, 2017, 'The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide', Cancer Treatment Reviews, 55, pp. 71 - 82, http://dx.doi.org/10.1016/j.ctrv.2017.03.001

Clingan PR; Ackland SP; Ranson M; De Souza P; Tafreshi A; Aghmesheh M; Brungs D; Garg MB; Parker S; Jokela R, 2017, 'Phase 1 study of infusional or bolus deflexifol (a novel formulation of 5FU, folinic acid, and cyclodextrin) after failure of standard treatment.', Journal of Clinical Oncology, 35, pp. TPS812 - TPS812, http://dx.doi.org/10.1200/jco.2017.35.4_suppl.tps812

Aslan P; Clark W; Patel M; Vass J; Cade DN; de Silva SJ; de Souza PL, 2017, 'MP16-12 SELECTIVE INTERNAL RADIATION THERAPY (SIRT) WITH YTTRIUM-90 (Y-90) RESIN MICROSPHERES IN PATIENTS WITH PRIMARY RENAL CELL CARCINOMA (RCC): IMPACT ON RENAL FUNCTION AND QUALITY OF LIFE IN THE RESIRT STUDY', Journal of Urology, 197, http://dx.doi.org/10.1016/j.juro.2017.02.518

Reardon DA; Omuro A; Brandes AA; Rieger J; Wick A; Sepulveda J; Phuphanich S; de Souza P; Ahluwalia MS; Lim M; Vlahovic G; Sampson J, 2017, 'OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143', Neuro-Oncology, 19, pp. iii21 - iii21, http://dx.doi.org/10.1093/neuonc/nox036.071

Aslan P; Clark W; Patel M; Vass J; Cade D; De Silva SJ; De Souza P, 2017, 'Renal function after selective internal radiation therapy (SIRT) with yttrium-90 (Y-90) resin microspheres in patients with primary renal cell carcinoma (RCC): The RESIRT study', European Urology Supplements, 16, pp. e630 - e631, http://dx.doi.org/10.1016/s1569-9056(17)30424-4

Clark W; Aslan P; Patel M; Vass J; Cade D; de Silva S; De Souza P, 2017, 'The RESIRT study: feasibility and dosimetry considerations of selective internal radiation therapy (SIRT) using yttrium-90 (Y-90) resin microspheres in patients with primary renal cell carcinoma (RCC)', Journal of Vascular and Interventional Radiology, 28, pp. S164 - S164, http://dx.doi.org/10.1016/j.jvir.2016.12.1001

Ho V; Chung L; Revoltar M; Lim SH; Tut TG; Abubakar A; Henderson CJ; Chua W; Ng W; Lee M; De Souza P; Morgan M; Lee CS; Shin JS, 2016, 'MRE11 and ATM expression levels predict rectal cancer survival and their association with radiotherapy response', PLoS ONE, 11, http://dx.doi.org/10.1371/journal.pone.0167675

Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ, 2016, 'The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy', Clinical Colorectal Cancer, 15, pp. 285 - 291, http://dx.doi.org/10.1016/j.clcc.2016.07.007

Wang H; Markman B; de Souza P; Dees EC; Gangadhar TC; Piha-Paul SA; Zamboni WC; Murphy C; Senderowicz A, 2016, 'A dose-escalation study of weekly intravenous CRLX301 in patients with advanced solid tumor malignancies', ANNALS OF ONCOLOGY, 27, http://dx.doi.org/10.1093/annonc/mdw368.56

Powles TB; Escudier B; de Souza P; Chowdhury S; Pook D; Harmenberg U; Basappa N; Geynisman D; Merchan J; Redman BG; Ryan C; Goodman O; Ho T; Singh P; Lougheed J; Patel M; Knox JJ; Motzer RJ; Choueiri TK, 2016, 'Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial', Annals of Oncology, 27, pp. vi284, http://dx.doi.org/10.1093/annonc/mdw373.41

de Souza P; Chua W; Clarke S; Goldstein D; Lee C, 2016, 'Inflammatory Markers Have a Role in Renal Cell Carcinoma Prognosis', European Urology Focus, 2, pp. 341 - 342, http://dx.doi.org/10.1016/j.euf.2016.04.007

de Souza P; Aslan P; Clark W; Patel M; Vass JA; Cade D; de Silva SJ, 2016, 'Phase 1 study of selective internal radiation therapy (SIRT) with yttrium-90 (Y-90) resin microspheres in patients (pts) with renal cell carcinoma (RCC): RESIRT', ANNALS OF ONCOLOGY, 27, http://dx.doi.org/10.1093/annonc/mdw373.31

Ma Y; Luk A; Young FP; Lynch D; Chua W; Balakrishnar B; de Souza P; Becker TM, 2016, 'Droplet digital PCR based androgen receptor variant 7 (AR-V7) detection from prostate cancer patient blood biopsies', International Journal of Molecular Sciences, 17, http://dx.doi.org/10.3390/ijms17081264

Back to profile page